Mechanism of Local Anesthetic Neurotoxicity and Detection of the Toxic Concentration

局麻药神经毒性机制及毒性浓度检测

基本信息

  • 批准号:
    12671478
  • 负责人:
  • 金额:
    $ 2.05万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2000
  • 资助国家:
    日本
  • 起止时间:
    2000 至 2002
  • 项目状态:
    已结题

项目摘要

We advocated that an irreversible neural injury induced by highly concentrated local anesthetics resulted from neural membrane disruption caused by local anesthetic solubilizing action, and investigated to prove it.1) We showed that local anesthetics clinically used formed the molecular self-aggregation at high concentration as a typical detergent did This result demonstrated that local anesthetics had same characteristics with a common surfactant.2) From the measurement of light scattering in the membrane dispersion mixed with local anesthetics, we obtained the concentration at which local anesthetics disrupted the phospholipid model membrane. Those concentrations were identical to those of critical micellar concentration. This result demonstrated that the detergent nature of highly concentrated local anesthetics disrupted the membrane.3) We studied whether a irreversible neural injury in rat occur at local anesthetic concentration that model membrane was disrupted. The concentrations … More at which dibucaine and lidocaine intrathecally administered caused irreversible neurological deficits were almost equal to critical concentrations at which model membrane was disrupted by local anesthetics. This result confirmed our hypothesis that an irreversible neural injury induced by highly concentrated local anesthetics resulted from neural membrane disruption caused by local anesthetic solubilizing action.4) By using small bore catheter (31G), we developed the new model rat for spinal anesthesia with less spinal injury at an intrathecal catheter implantation comparing to conventional method.5) We firstly applied a neurometer to a assessment of neurological injury in rat induced by lidocaine, and demonstrated that the assessment by this device war superior then that by conventional one.6) We demonstrated that anesthetic-induced hemolysis concentrations were good agreement with their neurotoxic concentrations accessed by animal study. Our results confirm that local anesthetic- induced nerve injury come from membrane disruption caused by anesthetic. This hemolysis study system appears to be a simple and basic model for resolving the mechanism of local anesthetic neurotoxicity. Less
我们主张高浓度局麻药引起的不可逆神经损伤是由于局麻药的增溶作用引起神经膜的破坏,并通过研究证明了这一点。1)我们证明了临床上使用的局麻药作为一种典型的洗涤剂在高浓度时形成了分子自聚集,这一结果证明了局麻药与普通表面活性剂具有相同的特性。2)通过测量局麻药与局麻药混合分散膜中的光散射,我们得到了局麻药破坏磷脂模型膜的浓度。这些浓度与临界胶束浓度相同。这一结果表明高浓度局麻药的去污性破坏了膜。3)我们研究了模型膜被破坏的局麻药浓度是否会对大鼠产生不可逆神经损伤。《…的浓度》此外,鞘内注射地布卡因和利多卡因导致的不可逆神经功能障碍几乎等于局部麻醉剂破坏模型膜的临界浓度。这一结果证实了我们的假设,即高浓度局麻药诱导的不可逆神经损伤是由于局麻药增溶作用导致神经膜破裂所致。4)与传统方法相比,我们使用小口径导管(31G)建立了鞘内置管脊髓麻醉的新模型大鼠。5)我们首次应用神经纤维计对利多卡因诱导的大鼠神经损伤进行了评估,并证明该装置的评估优于传统方法。6)我们证明麻醉剂诱导的溶血浓度与动物实验获得的神经毒性浓度具有良好的一致性。我们的结果证实了局麻药所致的神经损伤是由麻醉剂引起的膜破裂所致。该溶血研究系统为解决局麻药神经毒性的机制提供了一个简单而基本的模型。较少

项目成果

期刊论文数量(22)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
北川範仁, 小田万友子, 十時忠秀: "局所麻酔薬に関する最近の知見"麻酔. 50. S71-S81 (2001)
Norihito Kitakawa、Mayuko Oda、Tadahide Totoki:“局部麻醉的最新发现” 50. S71-S81 (2001)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
北川範仁, 小田万友子, 桜田琢, 楊邦祥, 十時忠秀, 森本正敏: "ニューロメータによるクモ膜下リドカイン投与後の神経損傷の評価"麻酔. 50. 453 (2001)
Norihito Kitakawa、Mayuko Oda、Taku Sakurada、Kuniyoshi Yang、Tadahide Totoki、Masatoshi Morimoto:“使用神经计评估鞘内利多卡因给药后的神经损伤” 麻醉 50. 453 (2001)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
N. Kitagawa, M. Oda, T. Sakurada, T. Miyabe, T. Totoki, T. Hotokebuchi: "Does Intrathecal Morphine Have Advantage In Postoperative Pain Relief After Total Hip Arthroplasty?"Regional Anesthesia and Pain medicine. PE-69. (2002)
N. Kitakawa、M. Oda、T. Sakurada、T. Miyabe、T. Totoki、T. Hotokebuchi:“鞘内注射吗啡在全髋关节置换术后镇痛方面有优势吗?”区域麻醉和疼痛医学。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
宮部崇: "電流刺激閾値を用いたクモ膜下リドカイン投与後の神経損傷の評価"麻酔. (in press). (2001)
Takashi Miyabe:“使用电流刺激阈值进行鞘内利多卡因给药后的神经损伤评估”(出版中)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
小田可友子: "リモ膜下リドカイン投与による神経障害の免疫組織学的評価"麻酔. (in press). (2001)
Kayoko Oda:“鞘内注射利多卡因引起的神经病变的免疫组织学评估”麻醉(2001 年出版)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KITAGAWA Norihito其他文献

KITAGAWA Norihito的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Small Molecule Degraders of Tryptophan 2,3-Dioxygenase Enzyme (TDO) as Novel Treatments for Neurodegenerative Disease
色氨酸 2,3-双加氧酶 (TDO) 的小分子降解剂作为神经退行性疾病的新疗法
  • 批准号:
    10752555
  • 财政年份:
    2024
  • 资助金额:
    $ 2.05万
  • 项目类别:
Impact of Mitochondrial Lipidomic Dynamics and its Interaction with APOE Isoforms on Brain Aging and Alzheimers Disease
线粒体脂质组动力学及其与 APOE 亚型的相互作用对脑衰老和阿尔茨海默病的影响
  • 批准号:
    10645610
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
Imaging Biomarkers of Neurotoxicity in Welders
焊工神经毒性的成像生物标志物
  • 批准号:
    10747199
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
Investigating Parkin-mediated Neuronal Energy Maintenance in Methamphetamine Use Disorder
研究甲基苯丙胺使用障碍中 Parkin 介导的神经元能量维持
  • 批准号:
    10736697
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
Targeting neuronal transport to ameliorate vincristine neurotoxicity
靶向神经元运输以改善长春新碱神经毒性
  • 批准号:
    10736789
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
Human Dopamine Grafts in Alpha-Synuclein Models of Parkinson Disease
帕金森病α-突触核蛋白模型中的人多巴胺移植物
  • 批准号:
    10736403
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer
CAR T 细胞靶向间皮素并分泌靶向胰腺癌成纤维细胞的双特异性抗体
  • 批准号:
    10731635
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
A new in vivo zebrafish model to study alpha-synuclein aggregation in Lewy Body Disease
研究路易体病中α-突触核蛋白聚集的新体内斑马鱼模型
  • 批准号:
    10731005
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
Brain-targeted delivery of therapeutic molecules by exosomes derived from engineered human iPS cells: a potential therapeutic approach for Huntington's disease
通过源自工程化人类 iPS 细胞的外泌体向大脑靶向递送治疗分子:亨廷顿病的潜在治疗方法
  • 批准号:
    10588392
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
Liver Targeting Dihydroquinolizinone (DHQ) Molecules as Hepatitis B Virus Antivirals with Reduced Toxicity
肝脏靶向二氢喹嗪酮 (DHQ) 分子作为乙型肝炎病毒抗病毒药物,毒性降低
  • 批准号:
    10593566
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了